Research article

RNA-protein correlation of liver toxicity markers in HepaRG cells

Albert Braeuning¹, Almut Mentz², Felix F. Schmidt³, Stefan P. Albaum², Hannes Planatscher³, Jörn Kalinowski², Thomas O. Joos^3,4, Oliver Poetz^3,4, Dajana Lichtenstein¹[*]

EXCLI J 2020;19:Doc135

Abstract

The liver is a main target organ for the toxicity of many different compounds. While in general, in vivo testing is still routinely used for assessing the hepatotoxic potential of test chemicals, the use of in vitro models offers advantages with regard to throughput, consumption of resources, and animal welfare aspects. Using the human hepatoma cell line HepaRG, we performed a comparative evaluation of a panel of hepatotoxicity marker mRNAs and proteins after exposure of the cells to 30 different pesticidal active compounds comprising herbizides, fungicides, insecticides, and others. The panel of hepatotoxicity markers included nuclear receptor target genes, key players of fatty acid and bile acid metabolism-related pathways, as well as recently identified biomarkers of drug-induced liver injury. Moreover, marker genes and proteins were identified, for example, S100P, ANXA10, CYP1A1, and CYP7A1. These markers respond with high sensitivity to stimulation with chemically diverse test compounds already at non-cytotoxic concentrations. The potency of the test compounds, determined as an overall parameter of their ability to deregulate marker expression in vitro, was very similar between the mRNA and protein levels. Thus, this study does not only characterize the response of human liver cells to 30 different pesticides but also demonstrates that hepatotoxicity testing in human HepaRG cells yields well comparable results at the mRNA and protein levels. Furthermore, robust hepatotoxicity marker genes and proteins were identified in HepaRG cells.

Keywords: liver toxicity, in vitro testing, hepatocytes, relative potency factors, omics

Abbreviations

ACN, acetonitrile; AHR, aryl hydrocarbon receptor; AOP, adverse outcome pathway; CAR, constitutive androstane receptor; CYP, cytochrome P450; DMSO, dimethyl sulfoxide; FBS, fetal bovine serum; FA, formic acid; LC-MS, liquid chromatography-mass spectrometry; LOAEL, lowest observed adverse effect level; NOAEL, no observed adverse effect level; PBS, phosphate-buffered saline; PXR, pregnane-X-receptor; RPF, relative potency factor; TXP, Triple X Proteomics; WST, water-soluble tetrazolium

Introduction

The liver is a main target organ of a plethora of toxicants, including for example, certain drugs, industrial chemicals, pesticidal active compounds, natural toxins, environmental contaminants (Adams et al., 2005[1]; EFSA Scientific Committee et al., 2019[17]; Alexander, 2012[3]). In classic toxicological testing, hepatotoxicity of a test compound is determined in in vivo studies mainly conducted in rodents, based on detailed histopathological examination of tissue specimens after prolonged, repeated exposure to the test chemical (OECD, 2019[52]; Pradeep et al., 2016[60]). Hepatic responses to exposure to xenobiotics can be manifold. Often, adaptive responses are observed, as exemplified by hepatocyte hypertrophy and enlargement of the smooth endoplasmatic reticulum, which is frequently detected as a consequence of the induction of hepatocellular drug-metabolizing capacities following activation of drug metabolism-regulating nuclear receptors by foreign compounds (Maronpot et al., 2010[46]; Schulte-Hermann, 1979[63]). Such responses include, for example, regulation of gene transcription by the constitutive androstane receptor (CAR), the pregnane-X-receptor (PXR), or the aryl hydrocarbon receptor (AHR) (Maronpot et al., 2010[46]). The most prominent target genes of these receptors come from the cytochrome P450 (CYP) superfamily of genes encoding important phase I drug-metabolizing enzymes (Tompkins and Wallace, 2007[72]; Waxman, 1999[78]). Reactive compounds or CYP metabolism-generated intermediates, such as radicals and electrophiles, can cause oxidative stress to hepatocytes followed by cell death, whereas more subtle manifestations of toxicity often comprise alterations in crucial metabolic pathways of the hepatocytes. For example, disturbance of the balance of fatty acid synthesis and degradation may result in fatty liver cells, potentially giving rise to progression of hepatic steatosis to liver inflammation, cirrhosis, and cancer (Basaranoglu et al., 2013[9]; Leung and Nieto, 2013[43]; Sturgill and Lambert, 1997[70]). Another example is the disruption of bile acid synthesis and excretion leading to cholestatic livers (Padda et al., 2011[54]; Waxman, 1992[79]). Key genes and proteins affected by toxicants in such pathways have, in some cases, been assembled to so-called adverse outcome pathways (AOPs) which describe causal relationships of molecular events leading to adverse responses at the organ level (Ankley et al., 2010[4]; Leist et al., 2017[42]; Vinken, 2013[75]).

Animal studies are ethically disputed, rather cost- and time-consuming, especially in the case of repeated-dose studies, and questioned for their relevance to humans, due to possible species differences (Graham and Lake, 2008[21]; Hackam and Redelmeier, 2006[25]; Martignoni et al., 2006[47]). Thus, there is a need for establishing in vitro approaches using human cells in order to circumvent the aforementioned drawbacks. This holds especially true with respect to the testing of the effects of chemical mixtures. Here, testing of the multitude of possible combinations of individual compounds is not feasible using animal-based approaches. A plethora of in vitro hepatotoxicity studies have been conducted using either primary hepatocytes or permanent hepatoma-derived cell lines. Measured endpoints range from simple cell viability assays to the measurement of complex metabolic endpoints, transcriptional responses or proteomic alterations (Bale et al., 2014[7]; Kyffin et al., 2018[39]; Soldatow et al., 2013[68]).

Especially transcriptomic signatures have been used to help characterizing the toxicological mode of action of chemicals and to classify test compounds according to their mechanisms of toxicity. For example, a lot of research has been performed to distinguish genotoxic from non-genotoxic carcinogens using transcript-based omics approaches (Ellinger-Ziegelbauer et al., 2005[18]; Jennen et al., 2010[31]; Lee et al., 2013[40]). In addition, panels of common marker genes for hepatotoxicity have been identified from omics data using bioinformatic methods (Albrecht et al., 2019[2]; Grinberg et al., 2018[22]). In contrast to the lot of work that has been performed at the mRNA level, proteomic data on hepatotoxicity have been studied less extensively.

Even though mRNAs are generally translated in proteins, a direct correlation of transcript and protein levels of a certain gene cannot be expected, because additional layers of cellular regulation such as alterations in translation efficiency or protein stability may considerably affect the outcome of protein level determination (Gry et al., 2009[23]). Knowledge of the correlation of the RNA and protein level alterations can help to improve our understanding of in vitro systems for hepatocellular toxicity, and contribute to assess the relevance of RNA-based data sets. Therefore, we here performed a comparative characterization of transcript- and protein-level responses using 30 different pesticidal active compounds as test items. The human hepatocarcinoma cell line HepaRG was chosen as a test system, based on the high degree of similarity of these cells with human hepatocytes (Kanebratt and Andersson, 2008[32]).

Materials and Methods

Chemicals

Cyproconazole, epoxiconazole, and prochloraz were obtained from BASF or Syngenta, respectively. The batches used identical to what has been used in a previous study by Seeger et al. (2019[66]). All other pesticidal active compounds were purchased from Sigma (Taufkirchen, Germany) in the highest available purity, dissolved in DMSO (purity > 99 %; Carl Roth, Karlsruhe, Germany), and stored at -20 °C until further use. In vitro testing was performed up to the highest possible concentrations, limited by the compound-specific solubility in cell culture medium. All other chemicals were obtained from Sigma or Merck (Darmstadt, Germany) in the highest available purity.

Cell culture

Human HepaRG hepatocarcinoma cells were purchased from Biopredic International (Saint Grégoire, France) and seeded according to the manufacturer's protocol at densities of 9,000, 100,000, or 200,000 cells/well in 96-well, 12-well, or 6-well plates, respectively. For cultivation William's Medium E with 2 mM glutamine (PAN-Biotech, Aidenbach, Germany), 10 % (v/v) fetal bovine serum (FBS; FBS Good Forte EU approved; PAN-Biotech), 100 U/ml penicillin and 100 µg/ml streptomycin (Capricorn Scientific, Ebsdorfergrund, Germany), 0.05 % human insulin (PAA Laboratories GmbH, Pasching, Austria) and 50 µM hydrocortisone hemisuccinate (Sigma) were used. Cells were cultured under standard cell culture conditions (37 °C in a humidified atmosphere with 5 % CO₂). Cells were differentiated for 14 days, followed by 14 days in medium additionally containing 1.7 % DMSO. Differentiated HepaRG cells were pre-adapted to treatment medium (culture medium containing only 2 % FBS and 0.5 % DMSO) for 48 h prior to exposure in treatment medium for 24 h, with a final DMSO concentration of 0.5 %. Cell identity and differentiation status were checked microscopically. Differentiated HepaRG cells exhibit characteristic, unique morphological features, as provided by the manufacturer´s specifications as well as described in several publications (Cerec et al., 2007[11]; Guillouzo et al., 2007[24]; Parent et al., 2004[56]). Additionally, cells were routinely checked for the absence of mycoplasma contaminations.

Cell viability analysis

Viability of cells treated with pesticidal active compounds was analyzed in HepaRG cells using the WST-1 cell assay (Sigma-Aldrich, St. Louis, USA) as described by Luckert et al. (2018[45]). In brief, cells were seeded in 96-well plates and incubated with the respective test compound. Triton X-100 (0.01 %) served as a positive control for cytotoxicity. One hour before the end of incubation, 10 µl WST-1 reagent was added to each well containing 100 µl medium and incubated again for one hour. Afterwards, absorbance was measured at 450 nm and corrected by values measured at the reference wavelength of 620 nm, using an Infinite M200 Pro plate reader (Tecan, Männedorf, Switzerland). At least three independent biological replicates, each with six technical replicates per condition, were run.

Analysis of mRNA expression levels

Cells were seeded in 12-well plates and incubated for 24 h with the respective test compounds or solvent control (0.5 % DMSO). Afterwards, cells were washed twice with ice-cold phosphate-buffered saline (PBS) and lysed using 350 µl RLT buffer per well (RNeasy Mini Kit; Qiagen, Hilden, Germany) containing 3.5 µl β-mercaptoethanol. RNA was isolated according to the manufacturer's protocol. Additionally, potential DNA contaminations were removed by DNase digestion (RNase-Free DNA Set; Qiagen). For higher yields, RNA was eluted twice in 30 µl H₂O. RNA was quantified at 260 nm using a Tecan spectrometer (Tecan, Männedorf, Switzerland). For purity evaluation the 260 nm/280 nm absorbance ratio was determined and ratios > 1.8 were considered an acceptable RNA purity. RNA integrity was checked by micro-gel electrophoresis using the Agilent RNA 6000 Nano Kit in a Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Only RNAs with calculated RIN (RNA Integrity Number) values > 9 were used (quality ranging from 10, i.e. highly intact RNA to 1, i.e. completely degraded RNA). RNA samples were stored at -80 °C. Primer design for quantitative RT-PCR experiments (Supplementary Table 1Lichtenstein_17012020_supplementary_material.xlsx) was performed by using qPrimerDepot (Cui et al., 2006[12]) and RTPrimerDB (Lefever et al., 2008[41]) and was validated by melting curve analysis. Relative expression from treatment procedures against DMSO-treated Reference RNA of all 47 genes was analyzed using 30 ng total RNA and the SensiFAST™ SYBR® No-ROX Kit (Bioline, Luckenwalde, Deutschland). All measurements were conducted in triplicates from biological replicates on a LightCycler® 96 System (Roche, Basel, Schweiz) applying sample maximization as experimental plate design. Efficiency of gene amplification was calculated for each run with LinRegPCR (Ramakers et al., 2003[61]; Ruijter et al., 2009[62]). For calculation of relative expression - including normalization by three reference genes - the software REST384 (Pfaffl, 2001[57]; Pfaffl et al., 2002[58]) was applied.

Analysis of protein expression levels

Cells were seeded in 12-well plates and incubated for 24 h with the respective test compounds or solvent control (0.5 % DMSO). Afterwards, cells were washed twice with ice-cold PBS and lysed using 400 µl/well lysis buffer containing 1 % NP-40, 0.01 % sodium dodecyl sulfate (SDS); 0.15 M sodium chloride; 0.01 M sodium phosphate; 2 mM ethylenediaminetetraacetic acid (EDTA); and 2.5 U/ml benzonase at pH 7.2. After 1 h of shaking at 4 °C, lysates were collected and stored at -80 °C. After lysis, the protein concentration was determined using the bicinchoninic acid assay (Thermo Fisher Scientific, Waltham, USA). The manufacturer's protocol was used for this purpose. The samples were diluted 1:5 before analysis and the concentrations determined with the microplate reader BioTek ELx808 (BioTek, Winooski, USA) at a wavelength of 562 nm. This was followed by tryptic proteolysis. Triethanolamine (TEA) with a final concentration of 50 mM and lysis buffer was added to the samples, which were then denatured at 99 °C for five minutes. After cooling to room temperature, tris(2-carboxyethyl) phosphine (TCEP; final concentration 5 mM) was added. After shaking for 30 sec, iodoacetamide (IAA) with a final concentration of 10 mM was added and samples were shaken again for 30 min at room temperature in the dark. Proteolysis was initiated with the addition of trypsin (trypsin:protein ratio 1:40) and the samples were digested at 37 °C for either 2 or 16 h. To stop digestion, phenylmethanesulfonyl fluoride (PMSF) with a final concentration of 1 mM was added. The samples were centrifuged for 10 min at 13,000 x g to remove cell debris. Before the samples were analyzed by liquid chromatography-mass spectrometry (LC-MS), immunoprecipitation was performed. The sample was mixed with PBS containing CHAPS (3-[(3-cholamidopropyl) dimethylammonio] -1-propanesulfonate), internal isotopically labeled standard peptide and the respective antibodies to enrich the target analytes. Special antibodies (called Triple X Proteomics; TXP) were used. These TXP antibodies specifically recognize the last four amino acids of the C-terminus. Thus, an antibody can enrich not only one peptide but whole peptide groups at once (Poetz et al., 2009[59]). The complete immunoprecipitation was performed as described in Weiß et al. (2018[80]).

An Acclaim PepMap RSLC C18 (75 μm I.D. x 150 mm, 2 μm, Thermo Fisher Scientific, Waltham, USA) analytical column and a trapping column Acclaim PepMap 100 C18 μ precolumn (0.3 mm I.D. x 5 mm, 5 μm, Thermo Fisher Scientific, Waltham, USA) were used for LC-MS analysis. The samples were measured in parallel reaction monitoring (PRM). The method duration was either 20 min (for the CYP 17-plex with a flow rate of 0.3 µl/min and an oven temperature of 40 °C) or 10 min (for all other multiplex assays with a flow rate of 1 µl/min and an oven temperature of 55 °C). Eluent A (aqueous phase) consisted of LC-MS grade water, with 0.1 % formic acid (FA) added. Eluent B (organic phase) of 80 % acetonitrile (ACN) and 20 % LC-MS grade water with 0.1 % FA. As loading buffer, 2 % ACN with LC-MS grade water and 0.05 % trifluoroacetic acid (TFA) was used. The evaluation of the data was carried out via Skyline 4.2.0. 19072. The ratio of the obtained endogenous signal and the internal isotopically labeled standard peptide was calculated. For each analyte, only the most intense fragment ion (quantifier ion) was used. For each test substance, cells were treated three times. Each sample was measured and mean values were calculated from the biological replicates. Fold changes were obtained by referencing the results of the treatments to the solvent control.

Determination of compound potency

As recommended by EFSA (2011[14]; EFSA Scientific Committee et al., 2017[16]; Kortenkamp et al., 2009[38]) and described previously (Kienhuis et al., 2015[33]; Staal et al., 2018[69]), a benchmark dose (BMD) approach was used which is currently considered the most appropriate approach for deriving reference points. One kind of reference point obtained by this method is the relative potency of a compound. By scaling the concentration-response of one compound relatively against the concentration-response of another, i.e. the reference compound, the relative potency factor (RPF) was obtained as a scaling factor. Usually, RPFs are computed for a single parameter of interest, e.g. cytotoxicity or the induction of expression of a specific target gene. In the context of omics data, this would lead to a plethora of different RPFs and constitute a time-consuming and inefficient approach. To overcome this drawback we developed a strategy which considers all analytes obtained during transcriptomic or proteomics analysis applying confidence interval statistics. For this purpose, the width of the confidence interval of transcriptomic alterations as an equivalent for the overall degree of transcriptomic alterations by one compound was used. Thus, half the width of confidence interval - mathematically defined as the absolute error e and measure of the accuracy of the estimation of a parameter - is defined as the potency factor (equation 1).

There, e denotes the absolute error or potency factor, z denotes the (1-α/2)-quantile of standard normal distribution and α = 0.05, i.e. including 95 % of the values. The parameter σ reflects the standard deviation and n is the number of data points per experiment. Due to different tested concentrations a correction for compound concentration by which effect was achieved is additionally required. Thus, e was furthermore divided into the administered concentration per compound. The relative potencies were computed for all compounds against each other. The software tool Genesis 1.8.1 (Sturn et al., 2002[71]) was applied for Cluster analysis.

Results

Selection of hepatotoxicity markers and test compounds

A panel of candidate hepatotoxicity markers was assembled based on data from the literature and own previous studies (Grinberg et al., 2018[22]; Seeger et al., 2019[66]). The panel included various nuclear receptor target genes (e.g. from the cytochrome P450 (CYP) superfamily), key players of fatty acid and bile acid metabolism-related pathways as compiled in the AOPs for steatosis and cholestasis (e.g. (Mellor et al., 2016[49]; Vinken, 2015[74]; Vinken et al., 2013[76]), as well as genes recently identified as biomarkers for drug-induced liver injury (e.g. Albrecht et al., 2019[2]; Grinberg et al., 2018[22]). Following an initial screening approach with several hepatotoxic pesticides, some functionally redundant entries with very similar regulation (e.g. closely related CYP genes known to be affected by identical transcription factors), as well as some genes not expressed in HepaRG cells or not influenced by any of the test compounds were removed from the panel, resulting in a final number of 51 hepatotoxicity markers used for subsequent analyses. The selected markers are listed in Table 1(Tab. 1).

Pesticidal active compounds were selected as test chemicals with well-known toxicological profiles. In order to cover a broad spectrum of exposure-relevant pesticides, 30 different substances were chosen for in vitro testing (Table 2(Tab. 2)). These belong to various chemical classes of pesticides, namely: anilinopyrimidines, benzimidazoles, carboxamides / dicarboximides, dithiocarbamates, imidazoles, morpholines, neonicotinoids, organophosphates, phthalimides, phenylpyrazoles / pyrazoles, strobilurins, triazoles, and quaternary ammonium compounds (Table 2(Tab. 2)), with liver as their main target organ in vivo.

Cell viability testing

Using the WST-1 assay, all compounds were screened in HepaRG cells for 24 h regarding their cytotoxic potential, for the evaluation of suitable test concentrations for transcriptomic and proteomic analysis (data not shown). The highest non-cytotoxic concentrations from the WST-1 assay were selected for subsequent transcriptomic and proteomic analysis and are listed in Table 2(Tab. 2).

Transcriptomic and proteomic analysis of active compounds

Using the selected highest non-toxic concentration of each compound, mRNA expression of the 44 hepatotoxicity marker genes was determined in HepaRG cells. The complete dataset is contained in Supplementary Table 2Lichtenstein_17012020_supplementary_material.xlsx. In total, a heterogeneous response was recorded at the mRNA level, involving up- and downregulation as well as pronounced and more subtle responses. Data are summarized in Figure 1(Fig. 1). Individual examples of regulation of selected genes are provided in Figure 2(Fig. 2), showing the results for the preferentially upregulated genes e.g. S100P, the preferentially downregulated genes CYP7A1, and for e.g. NEAT1 showing only weak alterations upon pesticide treatment.

In order to obtain correlating data at the protein level, a set of multiplexed targeted MS-based assays was used, consisting of existing and newly developed assays. In total, quantitative determination of 24 proteins was performed, with 17 proteins corresponding to important marker genes already assayed at the mRNA level (Table 1(Tab. 1)). HepaRG cells were incubated with the same concentrations of pesticidal active compounds as used for the mRNA analyses. Total results can be found in Supplementary Table 3Lichtenstein_17012020_supplementary_material.xlsx and are visualized in Figure 3(Fig. 3). Selected protein level data are depicted in Figure 4(Fig. 4).

RNA-protein correlation of hepatotoxicity markers in HepaRG cells

Subsequently, correlation of the data obtained individually at the mRNA and protein levels was assessed. For each of the 17 hepatotoxicity markers for which mRNA and protein data were available, correlations were analyzed. This is exemplarily depicted for S100P, NQO1, CYP2C9, and HSD11B2 in Figure 5(Fig. 5). The full datasets are available in Supplementary Tables 2 and 3Lichtenstein_17012020_supplementary_material.xlsx. Similar to S100P, CYP1A1, and TNFRSF12A also predominantly showed a consistent upregulation at the mRNA and protein levels by most chemicals (Figure 5(Fig. 5); and data not shown). Predominant downregulation at both, the mRNA and protein levels was observed for ADH1B, ARG1, CYP2C9, CYP2E1, SULT1B1, and UGT2B7 (Figure 5(Fig. 5); and data not shown). A tendency for that behavior was also seen for CYP7A1; however, the fact that protein levels of CYP7A1 were below the LOQ in several samples impeded comprehensive comparative analysis of this marker gene/protein (data not shown). A positive correlation between mRNA and protein data was also visible for ALDH3A1, FASN, and POR, even though a considerable number of deviations (8, 9, and 12 out of 30 compounds, respectively) from consistent up- or downregulation in the two datasets were recorded (data not shown). A comparable weak regulation of NQO1, without clear preference for up- or downregulation by a majority of compounds, was seen at the mRNA as well as protein levels (Figure 5(Fig. 5)). Inverse correlation of the direction of regulation was only observed for 2 of the 17 mRNAs/proteins, namely LMNA and PRKDC (data not shown). For HSD11B2, downregulation of mRNA expression but no clear-cut regulation at the protein was visible, possibly indicating a delayed response at the protein level (Figure 5(Fig. 5)). Overall, these findings point towards an overall good accordance of the responses obtained at the transcriptional and proteomic levels.

Omics-derived relative potency factors

In addition to the qualitative correlation of the direction of responses at the level of individual genes or proteins, we were also interested in comparing the overall relative potencies of the test compounds to alter RNA and protein levels on a broader basis. For this purpose, we decided to use relative potency factors derived by a benchmark dose approach. Such potency factors constitute a useful compound-characterizing parameter that is usually related to one specific biological endpoint, e.g. CYP3A4 expression. To adapt this approach to multi-endpoint data as resulting from omics analysis, the development of a strategy that considers the whole dataset needs to be developed. For this purpose, we developed a method that uses the width of the confidence interval of transcriptomic or proteomic alterations as an equivalent for the overall degree of transcriptomic alterations by one compound, independent of the nature of the specific genes or proteins that were subject to regulation. The mathematical background of the total omics RPF approach is described in detail in the 'Materials and Methods' section, paragraph 'Determination of compound potency'. This way, we were able to deduce RPFs for all compounds, based on their ability to deregulate gene or protein expression in HepaRG cells. Heatmap visualization of the RPFs is presented in Figure 6A(Fig. 6). For a full table of RPFs, please refer to Supplementary Table 4Lichtenstein_17012020_supplementary_material.xlsx. When comparing the RPFs derived from transcriptomic and proteomic analysis, it became evident that a high degree of concordance was present in the two datasets, i.e. that compounds which strongly altered the transcriptomic pattern of HepaRG cells were also potent at the protein level. Correlation analysis resulted in an R² value of 0.9515 (Figure 6B(Fig. 6)) with difenoconazole (DIF), fenpyroximate (FPX), and pyraclostrobin (PCL) being identified as the most potent compounds.

Discussion

The present work on the regulation of hepatotoxicity markers in HepaRG cells shows an overall good correlation between changes at the mRNA and protein levels, suggesting a considerable degree of comparability of the data obtained at the mRNA and protein levels. The broad response of HepaRG cells to the various hepatotoxic compounds underlines their usefulness as an in vitro model system for human liver cells. Interestingly, many genes show a uniform-type response, which means that they are generally either down- or upregulated by most of the test compounds. This is remarkable, as there is high chemical diversity among the thirty test compounds, connected to a variety of different molecular targets resulting in different mechanisms of toxicity. For some genes, it might be expected to observe such a pattern. Such an example could be a nuclear receptor target gene with low constitutive expression and pronounced inducibility, for example the AHR target CYP1A1 (Barouki et al., 2007[8]; Schulthess et al., 2015[64]). As not only classic AHR ligands such as dioxins, but also weaker, non-prototypical ligands can affect CYP1A1 expression, an induction by many test compounds is plausible. Of note, weak activation of AHR-dependent transcription has been published for some of the compounds used here, for example propiconazole (Knebel et al., 2018[37], 2019[35]), tebuconazole (Knebel et al., 2019[36]), prochloraz (Heise et al., 2015[28], 2018[27]; Vinggaard et al., 2006[73]).

Nonetheless, the hepatotoxicity marker panel presented here contains a substantial number of genes or proteins that are not directly linked to up-regulation by xenobiotic-activated nuclear receptors; and many of these genes show a tendency for regulation in a specific direction by mechanistically very different compounds. This indicates that the respective genes represent rather general and robust markers of hepatocellular stress, both at the mRNA and protein level. Responses were recorded at non-cytotoxic concentrations indicating a higher sensitivity of these transcript-based markers, as compared to classic cell vitality or cytotoxicity assays. It should be noted that transcriptional classifiers for hepatotoxicity have been subject of previous research projects, using different cellular models and/or test compounds (Grinberg et al., 2018[22]; Seeger et al., 2019[66]). Using the total degree of deregulation of such non-pathway-specific hepatocellular toxicity markers as a global parameter, it may be possible to estimate the hepatotoxic potential of test compounds in vitro. Therefore, we assessed whether the determined in vitro RPFs would correlate with the potencies of the compound to exert hepatotoxicity in vivo. Here, no pronounced correlation of the in vitro RPFs with in vivo LOAELs/NOAELs (no/lowest observed adverse effect levels), the toxicity parameters classically deduced from in vivo studies, was observable. However, that outcome may rather be expected for different reasons: first, the NOAELs and LOAELs bear a high level of uncertainty related to study design. This involves, amongst others, parameters like duration of exposure and the choice of dose levels and species. Benchmark approaches may help to improve the latter issue, but one has to bear in mind that such an approach is not compatible with the dosing schemes of many published studies. Of note, RPFs and NOAELs/LOAELs derived from the same studies do not necessarily show a high degree of correlation (EFSA Panel on Plant Protection Products and their Residues, 2009[15]). Second, species differences may exist regarding the sensitivity to certain hepatotoxicants between rodents and humans and therefore the predictivity of animal NOAELs/ LOAELs for humans may be limited. Of note, also the NOAELs/LOAELs of different non-human species show considerable variance. For example, dioxin toxicity is at great variance between species (Scientic Committee on Food, 2000[65]). Species differences are especially relevant for agonists of nuclear receptors, where often considerable differences between species are observed. For example, hepatic effects of exposure to cyproconazole in rodents are thought to be mediated by CAR, whereas humanization of the receptor in transgenic mice drastically diminishes the response (Marx-Stoelting et al., 2017[48]). Instead, cyproconazole appears to mainly affect human PXR in vitro (Luckert et al., 2018[45]). Tumor induction by activators of CAR or the peroxisome proliferator-activated receptor (PPAR) alpha is frequently observed in rodents, while human relevance of the processes occurring downstream these receptors is questioned (Graham and Lake, 2008[21]; Holsapple et al., 2005[29]). Third, toxicokinetic aspects have to be taken into account. In vivo dosing can, therefore, not be easily translated into in vitro concentrations without having proper in vivo-in vitro extrapolation models available for the test compounds. Thus, limited correlation of toxic doses in vivo and responses in vitro does not necessarily relate to shortcomings of a chosen in vitro system and detailed inter-species and toxicokinetic knowledge of individual compounds is necessary to judge on the correlation of in vitro data with the outcome of in vivo toxicity studies.

However, even if quantitative statements about in vivo toxicity remain difficult, the present in vitro hepatotoxicity dataset may be helpful in a different context: xenobiotic-induced hepatotoxicity may become manifest in many different ways, such as hepatic cholestasis, steatosis, or hepatocellular necrosis. Future analyses will reveal whether the type of hepatotoxicity, e.g. steatosis, can be predicted using the in vitro hepatotoxicity marker panel. Furthermore, the presented approach may be helpful in mixture testing, both with respect to qualitative (e.g. will a certain type of hepatotoxicity be induced by a mixture with sufficient probability but not by the individual compounds alone) and quantitative (e.g. is the mixture more potent than the sum of the individual compounds) aspects. In addition, the parameter of total transcriptional deregulation can be used in mixture testing, for setting up test compound concentrations of a desired potency.

In summary, the present work illustrates the comparability of hepatotoxicity marker testing at the mRNA and protein levels in HepaRG cells. Cellular responses to 30 different pesticides were characterized, providing a basis for future analyses of mechanisms of their toxicity. Furthermore, a number of robust hepatotoxicity marker genes and proteins were identified in HepaRG cells.

Acknowledgements

The research leading to these results received funding from the German Federal Ministry of Education and Research (BMBF), (e:TOP; Combiomics 2), Grant 031L0118A/ B/C. We would like to thank Julia Sternbeck and Beatrice Rosskopp for their excellent technical support.

References

1. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ. 2005;172:899-905.

2. Albrecht W, Kappenberg F, Brecklinghaus T, Stoeber R, Marchan R, Zhang M, et al. Prediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations. Arch Toxicol. 2019;93:1609-37. doi:10.1007/s00204-019-02492-9

3. Alexander J, Benford D, Boobis A, Eskola M, Fink-Gremmels J, Fürst P, et al. Risk assessment of contaminants in food and feed. EFSA J. 2012;10:s1004. doi:10.2903/j.efsa.2012.s1004

4. Ankley GT, Bennett RS, Erickson RJ, Hoff DJ, Hornung MW, Johnson RD, et al. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem. 2010;29:730-41. doi:10.1002/etc.34

5. Arumugam T, Simeone DM, Schmidt AM, Logsdon CD. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem. 2004;279:5059-65.

6. Arumugam T, Simeone DM, Van Golen K, Logsdon CD. S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res. 2005;11:5356-64.

7. Bale SS, Vernetti L, Senutovitch N, Jindal R, Hegde M, Gough A, et al. In vitro platforms for evaluating liver toxicity. Exp Biol Med. 2014;239:1180-91.

8. Barouki R, Coumoul X, Fernandez-Salguero PM. The aryl hydrocarbon receptor, more than a xenobiotic‐interacting protein. FEBS Lett. 2007;581:3608-15.

9. Basaranoglu M, Basaranoglu G, Sentürk H. From fatty liver to fibrosis: a tale of “second hit”. World J Gastroenterol. 2013;19:1158-65.

10. Bonne G, Di Barletta MR, Varnous S, Bécane H-M, Hammouda E-H, Merlini L, et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nature Genet. 1999;21:285-8.

11. Cerec V, Glaise D, Garnier D, Morosan S, Turlin B, Drenou B, et al. Transdifferentiation of hepatocyte‐like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology. 2007;45:957-67.

12. Cui W, Taub DD, Gardner K. qPrimerDepot: a primer database for quantitative real time PCR. Nucl Acids Res. 2006;35(Suppl 1):D805-9.

13. Duan L, Zhmurov A, Barsegov V, Dima RI. Exploring the mechanical stability of the C2 domains in human synaptotagmin 1. J Phys Chem B. 2011;115:10133-46.

14. EFSA. Use of BMDS and PROAST software packages by EFSA Scientific Panels and Units for applying the Benchmark Dose (BMD) approach in risk assessment. EFSA Supporting Publications. 2011;8(2):113E. doi:10.2903/sp.efsa.2011.EN-113

15. EFSA Panel on Plant Protection Products and their Residues (PPR Panel). Scientific Opinion on risk assessment for a selected group of pesticides from the triazole group to test possible methodologies to assess cumulative effects from exposure through food from these pesticides on human health. EFSA J. 2009;7(9):1167. doi: 10.2903/j.efsa.2009.1167

16. EFSA Scientific Committee, Hardy A, Benford D, Halldorsson T, Jeger MJ, Knutsen KH, et al. Update: use of the benchmark dose approach in risk assessment. EFSA J. 2017;15(1):E04658. doi:10.2903/j.efsa.2017.4658

17. EFSA Scientific Committee, More SJ, Bampidis V, Benford D, Bennekou SH, Bragard C, et al. Guidance on harmonised methodologies for human health, animal health and ecological risk assessment of combined exposure to multiple chemicals. EFSA J. 2019;17(3):E05634. doi:10.2903/j.efsa.2019.5634

18. Ellinger-Ziegelbauer H, Stuart B, Wahle B, Bomann W, Ahr HJ. Comparison of the expression profiles induced by genotoxic and nongenotoxic carcinogens in rat liver. Mutat Res. 2005;575:61-84. doi:10.1016/j.mrfmmm.2005.02.004

19. Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med. 1999;341:1715-24.

20. Fujita K-i, Nagata K, Ozawa S, Sasano H, Yamazoe Y. Molecular cloning and characterization of rat ST1B1 and human ST1B2 cDNAs, encoding thyroid hormone sulfotransferases. J Biochem. 1997;122:1052-61.

21. Graham MJ, Lake BG. Induction of drug metabolism: species differences and toxicological relevance. Toxicology. 2008;254:184-91.

22. Grinberg M, Stöber RM, Albrecht W, Edlund K, Schug M, Godoy P, et al. Toxicogenomics directory of rat hepatotoxicants in vivo and in cultivated hepatocytes. Arch Toxicol. 2018;92:3517-33.

23. Gry M, Rimini R, Strömberg S, Asplund A, Pontén F, Uhlén M, et al. Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genom. 2009;10(1):365.

24. Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact. 2007;168:66-73. doi:10.1016/j.cbi.2006.12.003

25. Hackam DG, Redelmeier DA. Translation of research evidence from animals to humans. JAMA. 2006;296:1727-32.

26. Han H-J, Tokino T, Nakamura Y. CSR, a scavenger receptor-like protein with a protective role against cellular damage caused by UV irradiation and oxidative stress. Hum Mol Genet. 1998;7:1039-46.

27. Heise T, Schmidt F, Knebel C, Rieke S, Haider W, Geburek I, et al. Hepatotoxic combination effects of three azole fungicides in a broad dose range. Arch Toxicol. 2018;92:859-72.

28. Heise T, Schmidt F, Knebel C, Rieke S, Haider W, Pfeil R, et al. Hepatotoxic effects of (tri)azole fungicides in a broad dose range. Arch Toxicol. 2015;89:2105-17. doi:10.1007/s00204-014-1336-1

29. Holsapple MP, Pitot HC, Cohen SH, Boobis AR, Klaunig JE, Pastoor T, et al. Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci. 2005;89:51-6.

30. Inlay MA, Bhattacharya D, Sahoo D, Serwold T, Seita J, Karsunky H, et al. Ly6d marks the earliest stage of B-cell specification and identifies the branchpoint between B-cell and T-cell development. Genes Dev. 2009;23:2376-81.

31. Jennen DG, Magkoufopoulou C, Ketelslegers HB, van Herwijnen MH, Kleinjans JC, van Delft JH. Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010;115:66-79.

32. Kanebratt KP, Andersson TB. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos. 2008;36:1444-52. doi:10.1124/dmd.107.020016

33. Kienhuis AS, Slob W, Gremmer ER, Vermeulen JP, Ezendam J. A dose-response modeling approach shows that effects from mixture exposure to the skin sensitizers isoeugenol and cinnamal are in line with dose addition and not with synergism. Toxicol Sci. 2015;147:68-74.

34. Kligman D, Hilt DC. The S100 protein family. Trends Biochem Sci. 1988;13:437-43.

35. Knebel C, Buhrke T, Süssmuth R, Lampen A, Marx-Stoelting P, Braeuning A. Pregnane X receptor mediates steatotic effects of propiconazole and tebuconazole in human liver cell lines. Arch Toxicol. 2019a;93:1311-22.

36. Knebel C, Heise T, Zanger UM, Lampen A, Marx-Stoelting P, Braeuning A. The azole fungicide tebuconazole affects human CYP1A1 and CYP1A2 expression by an aryl hydrocarbon receptor-dependent pathway. Food Chem Toxicol. 2019b;123:481-91.

37. Knebel C, Kebben J, Eberini I, Palazzolo L, Hammer HS, Süssmuth RD, et al. Propiconazole is an activator of AHR and causes concentration additive effects with an established AHR ligand. Arch Toxicol. 2018;92:3471-86.

38. Kortenkamp A, Backhaus T, Faust M. State of the art report on mixture toxicity. Final Report. Executive summary. Directorate General for the Environment: Report to the EU Commission 2009;070307/2007/ 485103/ETU/D.1.

39. Kyffin JA, Sharma P, Leedale J, Colley HE, Murdoch C, Mistry P, et al. Impact of cell types and culture methods on the functionality of in vitro liver systems–a review of cell systems for hepatotoxicity assessment. Toxicol Vitro. 2018;48:262-75.

40. Lee SJ, Yum YN, Kim SC, Kim Y, Lim J, Lee WJ, et al. Distinguishing between genotoxic and non-genotoxic hepatocarcinogens by gene expression profiling and bioinformatic pathway analysis. Sci Rep. 2013;3:2783.

41. Lefever S, Vandesompele J, Speleman F, Pattyn F. RTPrimerDB: the portal for real-time PCR primers and probes. Nucl Acids Res. 2008;37(Suppl 1):D942-5.

42. Leist M, Ghallab A, Graepel R, Marchan R, Hassan R, Bennekou SH, et al. Adverse outcome pathways: opportunities, limitations and open questions. Arch Toxicol. 2017;91:3477-505. doi:10.1007/s00204-017-2045-3

43. Leung T-M, Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J Hepatol. 2013;58:395-8.

44. Lu SH, Yuan RH, Chen YL, Hsu HC, Jeng YM. Annexin A 10 is an immunohistochemical marker for adenocarcinoma of the upper gastrointestinal tract and pancreatobiliary system. Histopathology. 2013;63:640-8.

45. Luckert C, Braeuning A, de Sousa G, Durinck S, Katsanou ES, Konstantinidou P, et al. Adverse outcome pathway-driven analysis of liver steatosis in vitro: A case study with cyproconazole. Chem Res Toxicol. 2018;31:784-98. doi:10.1021/acs.chemrestox.8b00112

46. Maronpot RR, Yoshizawa K, Nyska A, Harada T, Flake G, Mueller G, et al. Hepatic enzyme induction: histopathology. Toxicol Pathol. 2010;38:776-95.

47. Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Exp Opin Drug Metab Toxicol. 2006;2:875-94.

48. Marx-Stoelting P, Ganzenberg K, Knebel C, Schmidt F, Rieke S, Hammer H, et al. Hepatotoxic effects of cyproconazole and prochloraz in wild-type and hCAR/hPXR mice. Arch Toxicol. 2017;91:2895-907.

49. Mellor CL, Steinmetz FP, Cronin MT. The identification of nuclear receptors associated with hepatic steatosis to develop and extend adverse outcome pathways. Crit Rev Toxicol. 2016;46:138-52. doi:10.3109/10408444.2015.1089471

50. Moss SE, Morgan RO. The annexins. Genome Biol. 2004;5(4):219.

51. Novelli G, Muchir A, Sangiuolo F, Helbling-Leclerc A, D’Apice MR, Massart C, et al. Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. Am J Hum Genet. 2002;71:426-31.

52. OECD. OECD guidelines for the testing of chemicals, Section 4. Paris: OECD, 2019. doi:https://doi.org/10.1787/20745788. Accessed 28 October 2019.

53. Ohuchida K, Mizumoto K, Egami T, Yamaguchi H, Fujii K, Konomi H, et al. S100P is an early developmental marker of pancreatic carcinogenesis. Clin Cancer Res.. 2006;12:5411-6.

54. Padda MS, Sanchez M, Akhtar AJ, Boyer JL. Drug‐induced cholestasis. Hepatology. 2011;53:1377-87.

55. Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology. 2007;132:330-42.

56. Parent R, Marion M-J, Furio L, Trépo C, Petit M-A. Origin and characterization of a human bipotent liver progenitor cell line. Gastroenterology. 2004;126:1147-56.

57. Pfaffl MW. A new mathematical model for relative quantification in real-time RT–PCR. Nucl Acids Res. 2001;29(9):e45.

58. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucl Acids Res. 2002;30(9):e36.

59. Poetz O, Hoeppe S, Templin MF, Stoll D, Joos TO. Proteome wide screening using peptide affinity capture. Proteomics. 2009;9:1518-23.

60. Pradeep P, Povinelli RJ, White S, Merrill SJ. An ensemble model of QSAR tools for regulatory risk assessment. J Cheminformat. 2016;8(1):48.

61. Ramakers C, Ruijter JM, Deprez RHL, Moorman AF. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett. 2003;339:62-6.

62. Ruijter J, Ramakers C, Hoogaars W, Karlen Y, Bakker O, Van den Hoff M, et al. Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucl Acids Res. 2009;37(6):e45.

63. Schulte-Hermann R. Adaptive liver growth induced by xenobiotic compounds: its nature and mechanism. In: Chambers PL, Günzel P (eds.): Mechanism of toxic action on some target organs (pp 113-24). Berlin: Springer, 1979. (Archives of Toxicology, Suppl. 2).

64. Schulthess P, Löffler A, Vetter S, Kreft L, Schwarz M, Braeuning A, et al. Signal integration by the CYP1A1 promoter—a quantitative study. Nucl Acids Res. 2015;43:5318-30.

65. Scientic Committee on Food. Opinion of the SCF on the Risk Assessment of Dioxins and Dioxin-like PCBs in Food. Brussel: European Commission, 2000. https://ec.europa.eu/food/sites/food/files/safety/docs/cs_contaminants_catalogue_dioxins_out90_en.pdf

66. Seeger B, Mentz A, Knebel C, Schmidt F, Bednarz H, Niehaus K, et al. Assessment of mixture toxicity of (tri)azoles and their hepatotoxic effects in vitro by means of omics technologies. Arch Toxicol. 2019;93:2321-33. doi:10.1007/s00204-019-02502-w

67. Smith EM, Zhang Y, Baye TM, Gawrieh S, Cole R, Blangero J, et al. INSIG1 influences obesity-related hypertriglyceridemia in humans. J Lipid Res. 2010;51:701-8.

68. Soldatow VY, LeCluyse EL, Griffith LG, Rusyn I. In vitro models for liver toxicity testing. Toxicol Res. 2013;2:23-39.

69. Staal YCM, Meijer J, van der Kris RJC, de Bruijn AC, Boersma AY, Gremmer ER, et al. Head skeleton malformations in zebrafish (Danio rerio) to assess adverse effects of mixtures of compounds. Arch Toxicol. 2018;92:3549-64. doi:10.1007/s00204-018-2320-y

70. Sturgill MG, Lambert GH. Xenobiotic-induced hepatotoxicity: mechanisms of liver injury and methods of monitoring hepatic function. Clin Chem. 1997;43:1512-26.

71. Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics. 2002;18 (1):207-8.

72. Tompkins LM, Wallace AD. Mechanisms of cytochrome P450 induction. J Biochem Mol Toxicol. 2007;21:176-81.

73. Vinggaard AM, Hass U, Dalgaard M, Andersen HR, Bonefeld-Jørgensen E, Christiansen S, et al. Prochloraz: an imidazole fungicide with multiple mechanisms of action. Int J Androl. 2006;29:186-92.

74. Vinken M. Adverse outcome pathways and drug-induced liver injury testing. Chem Res Toxicol. 2015;28:1391-7. doi:10.1021/acs.chemrestox.5b00208

75. Vinken M. The adverse outcome pathway concept: a pragmatic tool in toxicology. Toxicology. 2013;312:158-65.

76. Vinken M, Landesmann B, Goumenou M, Vinken S, Shah I, Jaeschke H, et al. Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury. Toxicol Sci. 2013;136:97-106.

77. Wang T, Ma S, Qi X, Tang X, Cui D, Wang Z, et al. Knockdown of the differentially expressed gene TNFRSF12A inhibits hepatocellular carcinoma cell proliferation and migration in vitro. Mol Med Rep. 2017;15:1172-8.

78. Waxman DJ. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys. 1999;369:11-23.

79. Waxman DJ. Regulation of liver-specific steroid metabolizing cytochromes P450: cholesterol 7α-hydroxylase, bile acid 6β-hydroxylase, and growth hormone-responsive steroid hormone hydroxylases. J Steroid Biochem Mol Biol. 1992;43:1055-72.

80. Weiß F, Hammer HS, Klein K, Planatscher H, Zanger UM, Norén A, et al. Direct quantification of cytochromes P450 and drug transporters—a rapid, targeted mass spectrometry-based immunoassay panel for tissues and cell culture lysates. Drug Metab Dispos. 2018;46:387-96.

81. Whelan FJ, Meehan CJ, Golding GB, McConkey BJ, Bowdish DM. The evolution of the class A scavenger receptors. BMC Evol Biol. 2012;12:227.

82. Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity. 2001;15:837-46.

83. Yang C, Li Z, Li Y, Xu R, Wang Y, Tian Y, et al. Long non-coding RNA NEAT1 overexpression is associated with poor prognosis in cancer patients: a systematic review and meta-analysis. Oncotarget. 2017;8:2672-80.

84. Yang T, Espenshade PJ, Wright ME, Yabe D, Gong Y, Aebersold R, et al. Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell. 2002;110:489-500.

85. Yu X, Li Z, Zheng H, Chan MT, Wu WKK. NEAT 1: A novel cancer‐related long non‐coding RNA. Cell Prolif. 2017;50(2):e12329.

86. Yu X, Zheng H, Chan MT, Wu WKK. HULC: an oncogenic long non‐coding RNA in human cancer. J Cell Mol Med. 2017;21:410-7.

 

 

File-Attachments

1. Lichtenstein_17012020_supplementary_material.xlsx (112,07 KB)
   Supplementary material

 

 

Figure 1: Hierarchical clustering (average linkage) method shows groups of downregulated genes (green) and upregulated genes (red) over all substances. Chlormequat, maneb, and thiram cluster most distant from all other compounds.

Figure 2: Representative deregulated transcripts in HepaRG cells after 24 h of treatment with 30 different pesticidal active compounds. Preferentially upregulated transcripts (a), preferentially downregulated transcripts (b), and transcripts with only weak alterations (c) are shown.

Figure 3: Hierarchical clustering method (average linkage) shows groups of downregulated proteins (green) and upregulated proteins (red) over all substances. Ethoprophos, maneb, and thiram cluster most distant from all other compounds.

Figure 4: Representative deregulated proteins in HepaRG cells after 24 h of treatment with 30 different pesticidal active compounds. Preferentially upregulated proteins (a), preferentially downregulated proteins (b), and proteins with only weak alterations (c) are shown. #, no endogenous protein levels detectable. Data below the lower limit of quantification (LLOQ) of 0.075 fmol/µg Protein (CYP1A1) are marked with ~.

Figure 5: RNA-protein correlation of different hepatotoxicity markers assayed in HepaRG cells treated with 30 pesticidal active compounds for 24 h. Representative examples of common upregulation (S100P; panel a), common downregulation (CYP2C9; panel b), common lack of regulation (NQO1; panel c), as well as regulation at the mRNA but not protein level (HSD11B2; panel d) are depicted. Each dot represents the mean data from mRNA and protein quantification resulting from treatment of HepaRG cells with an individual chemical.

Figure 6: Comparison of relative potencies obtained via transcriptomics and proteomics (a). The scale bar denotes higher or lower RPFs of a compound, as compared to another compound, in purple and blue, respectively. (b) Analysis of correlation of transcriptomic and proteomic RPFs. Each dot represents the RPF derived at the mRNA and protein levels for treatment with an individual compound.

 

Table 1: Selection of hepatotoxicity markers and their function

Table 2: Compound selection and tested concentrations in vitro

[*] Corresponding Author:

Dajana Lichtenstein, German Federal Institute for Risk Assessment, Dept. Food Safety, Max-Dohrn-Str. 8-10, 10589 Berlin, Germany; Phone +49-(0)30-18412-25126, Fax +49-(0)30-18412-63758, eMail: Dajana.Lichtenstein@bfr.bund.de